Sun Pharma tied US Medicaid prices to its floor.

The clause raises the cost of ever discounting drugs anywhere else.

India’s generics have stayed affordable across Africa and South Asia by charging different buyers different prices.

The deal also delays new US tariffs on Sun Pharma’s products by two years.

How each outlet framed it
Hindustan Times
highlights MFN Medicaid pricing agreement and 2-year Section 232 tariff deferral as Trump administration quid pro quo

Sources: Hindustan Times